Clinical Presentations, Predictive Factors, and Outcomes of Clostridioides difficile Infection among COVID-19 Hospitalized Patients—A Single Center Experience from the COVID Hospital of the University Clinical Center of Vojvodina, Serbia

Medicina (Kaunas). 2022 Sep 12;58(9):1262. doi: 10.3390/medicina58091262.

Abstract

Background: This study aimed to investigate the clinical form, risk factors, and outcomes of patients with COVID-19 and Clostridioides difficile co-infections. Methods: This retrospective study (2 September 2021-1 April 2022) included all patients with Clostridioides difficile infection (CDI) and COVID-19 infection who were admitted to the Covid Hospital of the University Clinical Center of Vojvodina. Results: A total of 5124 COVID-19 patients were admitted to the Covid Hospital, and 326 of them (6.36%) developed hospital-onset CDI. Of those, 326 of the CDI patients (88.65%) were older than 65 years. The median time of CDI onset was 12.88 days. Previous hospitalizations showed 69.93% of CDI patients compared to 38.81% in the non-CDI group (p = 0.029). The concomitant antibiotics exposure was higher among the CDI group versus the non-CDI group (88.65% vs. 68.42%, p = 0.037). Albumin levels were ≤ 25 g/L among 39.57% of the CDI patients and 21.71% in the non-CDI patients (p = 0.021). The clinical manifestations of CDI ranged from mild diarrhea (26.9%) to severe diarrhea (63.49%) and a complicated form of colitis (9.81%). Regarding outcomes, 79.14% of the CDI patients recovered and 20.86% had fatal outcomes in-hospital. Although a minority of the patients were in the non-CDI group, the difference in mortality rate between the CDI and non-CDI group was not statistically significant (20.86% vs. 15.13%, p = 0.097). Conclusions: Elderly patients on concomitant antibiotic treatments with hypoalbuminemia and with previous healthcare exposures were the most affected by COVID-19 and CD co-infections.

Keywords: COVID-19; Clostridioides difficile infection; antibiotics; risk factors.

MeSH terms

  • Aged
  • Albumins
  • Anti-Bacterial Agents / therapeutic use
  • COVID-19* / complications
  • Clostridioides difficile*
  • Clostridium Infections* / complications
  • Clostridium Infections* / drug therapy
  • Clostridium Infections* / epidemiology
  • Coinfection* / epidemiology
  • Diarrhea / epidemiology
  • Diarrhea / etiology
  • Hospitals
  • Humans
  • Retrospective Studies
  • Serbia / epidemiology
  • Universities
  • Yugoslavia

Substances

  • Albumins
  • Anti-Bacterial Agents

Grants and funding

This research received no external funding.